2016 Q2 Form 10-Q Financial Statement
#000156459016019363 Filed on May 13, 2016
Income Statement
| Concept | 2016 Q2 | 2016 Q1 | 2015 Q4 |
|---|---|---|---|
| Revenue | $400.0K | $396.6K | $360.0K |
| YoY Change | 252.0% | ||
| Cost Of Revenue | |||
| YoY Change | |||
| Gross Profit | |||
| YoY Change | |||
| Gross Profit Margin | |||
| Selling, General & Admin | $1.020M | $1.110M | $1.040M |
| YoY Change | 5.15% | 37.04% | 50.72% |
| % of Gross Profit | |||
| Research & Development | $3.570M | $2.174M | $1.820M |
| YoY Change | 109.11% | 200.5% | 219.3% |
| % of Gross Profit | |||
| Depreciation & Amortization | $20.00K | $17.29K | $10.00K |
| YoY Change | 221.82% | ||
| % of Gross Profit | |||
| Operating Expenses | $4.590M | $3.284M | $2.870M |
| YoY Change | 71.5% | 113.89% | 127.78% |
| Operating Profit | -$2.887M | ||
| YoY Change | 88.06% | ||
| Interest Expense | $0.00 | $6.430K | $0.00 |
| YoY Change | -100.0% | 556.79% | |
| % of Operating Profit | |||
| Other Income/Expense, Net | -$5.017K | $0.00 | |
| YoY Change | 1097.37% | ||
| Pretax Income | -$4.190M | -$2.890M | -$2.500M |
| YoY Change | 63.67% | 87.66% | 98.41% |
| Income Tax | |||
| % Of Pretax Income | |||
| Net Earnings | -$4.190M | -$2.892M | -$2.500M |
| YoY Change | 63.51% | 88.33% | 98.41% |
| Net Earnings / Revenue | -1047.5% | -729.26% | -694.44% |
| Basic Earnings Per Share | |||
| Diluted Earnings Per Share | -$108.1K | -$76.84K | -$66.37K |
| COMMON SHARES | |||
| Basic Shares Outstanding | 37.61M | 37.61M | |
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2016 Q2 | 2016 Q1 | 2015 Q4 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $22.00M | $9.688M | $12.34M |
| YoY Change | 138.01% | 94.87% | 97.02% |
| Cash & Equivalents | $22.00M | $9.688M | $12.34M |
| Short-Term Investments | $0.00 | $0.00 | |
| Other Short-Term Assets | $300.0K | $500.0K | $400.0K |
| YoY Change | 50.0% | 150.0% | 33.33% |
| Inventory | |||
| Prepaid Expenses | $474.6K | $376.5K | |
| Receivables | |||
| Other Receivables | |||
| Total Short-Term Assets | $22.30M | $10.16M | $12.71M |
| YoY Change | 134.93% | 96.1% | 94.62% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $300.0K | $296.5K | $124.1K |
| YoY Change | 410.86% | 488.36% | 129.7% |
| Goodwill | |||
| YoY Change | |||
| Intangibles | |||
| YoY Change | |||
| Long-Term Investments | |||
| YoY Change | |||
| Other Assets | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Total Long-Term Assets | $300.0K | $332.9K | $160.5K |
| YoY Change | 314.05% | 419.12% | 136.84% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $22.30M | $10.16M | $12.71M |
| Total Long-Term Assets | $300.0K | $332.9K | $160.5K |
| Total Assets | $22.60M | $10.50M | $12.88M |
| YoY Change | 136.28% | 100.05% | 95.06% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $2.000M | $1.230M | $1.314M |
| YoY Change | 87.05% | 553.46% | 281.91% |
| Accrued Expenses | $1.900M | $1.298M | $562.3K |
| YoY Change | 387.13% | 341.51% | 125.37% |
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | $0.00 | $100.0K | $200.0K |
| YoY Change | 0.0% | 100.0% | |
| Total Short-Term Liabilities | $5.000M | $4.076M | $3.630M |
| YoY Change | 113.6% | 634.79% | 391.85% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Other Long-Term Liabilities | $0.00 | $14.85K | $300.0K |
| YoY Change | -100.0% | ||
| Total Long-Term Liabilities | $0.00 | $14.85K | $300.0K |
| YoY Change | -100.0% | ||
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $5.000M | $4.076M | $3.630M |
| Total Long-Term Liabilities | $0.00 | $14.85K | $300.0K |
| Total Liabilities | $5.000M | $4.091M | $3.890M |
| YoY Change | 78.85% | 637.47% | 427.11% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$16.17M | -$13.28M | |
| YoY Change | 171.18% | 199.92% | |
| Common Stock | $22.57M | $22.26M | |
| YoY Change | 868133.15% | 116.36% | |
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | $17.70M | $6.404M | $8.985M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $22.60M | $10.50M | $12.88M |
| YoY Change | 136.28% | 100.05% | 95.06% |
Cashflow Statement
| Concept | 2016 Q2 | 2016 Q1 | 2015 Q4 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$4.190M | -$2.892M | -$2.500M |
| YoY Change | 63.51% | 88.33% | 98.41% |
| Depreciation, Depletion And Amortization | $20.00K | $17.29K | $10.00K |
| YoY Change | 221.82% | ||
| Cash From Operating Activities | -$2.530M | -$2.510M | -$880.0K |
| YoY Change | -12750.0% | 96.09% | -33.33% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | -$120.0K | $65.32K | -$90.00K |
| YoY Change | 500.0% | 3682.4% | |
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | |||
| YoY Change | |||
| Cash From Investing Activities | -$120.0K | -$70.00K | -$90.00K |
| YoY Change | 500.0% | ||
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | |||
| YoY Change | |||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | 14.99M | -70.00K | 160.0K |
| YoY Change | 251.05% | 600.0% | 220.0% |
| NET CHANGE | |||
| Cash From Operating Activities | -2.530M | -2.510M | -880.0K |
| Cash From Investing Activities | -120.0K | -70.00K | -90.00K |
| Cash From Financing Activities | 14.99M | -70.00K | 160.0K |
| Net Change In Cash | 12.34M | -2.650M | -810.0K |
| YoY Change | 188.99% | 105.43% | -36.22% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$2.530M | -$2.510M | -$880.0K |
| Capital Expenditures | -$120.0K | $65.32K | -$90.00K |
| Free Cash Flow | -$2.410M | -$2.575M | -$790.0K |
| YoY Change | -6125.0% | 100.93% | -40.15% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2016Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
9687805 | |
| CY2015Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
12338275 | |
| CY2016Q1 | us-gaap |
Prepaid Expense Current
PrepaidExpenseCurrent
|
474560 | |
| CY2016Q1 | dei |
Entity Filer Category
EntityFilerCategory
|
Smaller Reporting Company | |
| CY2016Q2 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
37606165 | |
| CY2015Q4 | us-gaap |
Prepaid Expense Current
PrepaidExpenseCurrent
|
376515 | |
| CY2016Q1 | us-gaap |
Assets Current
AssetsCurrent
|
10162365 | |
| CY2015Q4 | us-gaap |
Assets Current
AssetsCurrent
|
12714790 | |
| CY2016Q1 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
296534 | |
| CY2015Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
124138 | |
| CY2016Q1 | us-gaap |
Assets
Assets
|
10495274 | |
| CY2015Q4 | us-gaap |
Assets
Assets
|
12875303 | |
| CY2016Q1 | us-gaap |
Notes Payable Current
NotesPayableCurrent
|
92958 | |
| CY2016Q1 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
1230449 | |
| CY2016Q1 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
1297988 | |
| CY2015Q4 | us-gaap |
Marketable Securities
MarketableSecurities
|
0 | |
| CY2015Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-13277814 | |
| CY2015Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
3630033 | |
| CY2015Q4 | us-gaap |
Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
|
260260 | |
| CY2016Q1 | us-gaap |
Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
|
36375 | |
| CY2015Q4 | us-gaap |
Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
|
36375 | |
| CY2015Q4 | us-gaap |
Notes Payable Current
NotesPayableCurrent
|
162019 | |
| CY2015Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
1314377 | |
| CY2015Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
562279 | |
| CY2016Q1 | us-gaap |
Deferred Revenue Current
DeferredRevenueCurrent
|
1455020 | |
| CY2015Q4 | us-gaap |
Deferred Revenue Current
DeferredRevenueCurrent
|
1591358 | |
| CY2016Q1 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
4076415 | |
| CY2016Q1 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
14852 | |
| CY2016Q1 | us-gaap |
Liabilities
Liabilities
|
4091267 | |
| CY2015Q4 | us-gaap |
Liabilities
Liabilities
|
3890293 | |
| CY2016Q1 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2015Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2016Q1 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
| CY2015Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
| CY2016Q1 | us-gaap |
Common Stock Value
CommonStockValue
|
3761 | |
| CY2015Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
723430 | |
| CY2016Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
6404007 | |
| CY2015Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
3761 | |
| CY2016Q1 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
22570301 | |
| CY2015Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
22259063 | |
| CY2016Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-16170055 | |
| CY2016Q1 | us-gaap |
Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
|
343 | |
| CY2016Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-5017 | |
| CY2015Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-419 | |
| CY2016Q1 | us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
-396598 | |
| CY2015Q1 | us-gaap |
Interest Expense
InterestExpense
|
979 | |
| CY2016Q1 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
1070 | |
| CY2015Q1 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
560 | |
| CY2016Q1 | us-gaap |
Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
|
7905 | |
| CY2016Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-2514968 | |
| CY2015Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
8985010 | |
| CY2016Q1 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
10495274 | |
| CY2015Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
12875303 | |
| CY2016Q1 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.0001 | |
| CY2015Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.0001 | |
| CY2016Q1 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | |
| CY2015Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | |
| CY2016Q1 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
| CY2015Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
| CY2016Q1 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
| CY2015Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
| CY2016Q1 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
150000000 | |
| CY2015Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
150000000 | |
| CY2016Q1 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
37605827 | |
| CY2015Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
37605134 | |
| CY2016Q1 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
37605827 | |
| CY2015Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
37605134 | |
| CY2016Q1 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
| CY2015Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
| CY2016Q1 | us-gaap |
Revenues
Revenues
|
396598 | |
| CY2016Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
2173933 | |
| CY2016Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
1109889 | |
| CY2015Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
811869 | |
| CY2016Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
3283822 | |
| CY2015Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
1535299 | |
| CY2016Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-2887224 | |
| CY2015Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-1535299 | |
| CY2016Q1 | us-gaap |
Interest Expense
InterestExpense
|
6430 | |
| CY2016Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-2892241 | |
| CY2015Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-1535718 | |
| CY2016Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.08 | |
| CY2015Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.06 | |
| CY2016Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
37605210 | |
| CY2015Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
25871796 | |
| CY2016Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
311238 | |
| CY2015Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
301958 | |
| CY2016Q1 | us-gaap |
Depreciation
Depreciation
|
17285 | |
| CY2015Q1 | us-gaap |
Depreciation
Depreciation
|
5371 | |
| CY2015Q1 | us-gaap |
Increase Decrease In Restricted Cash For Operating Activities
IncreaseDecreaseInRestrictedCashForOperatingActivities
|
2 | |
| CY2016Q1 | us-gaap |
Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
|
98045 | |
| CY2015Q1 | us-gaap |
Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
|
-59805 | |
| CY2016Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-196648 | |
| CY2015Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-155862 | |
| CY2016Q1 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
732136 | |
| CY2015Q1 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
44498 | |
| CY2015Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-1279950 | |
| CY2016Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
65322 | |
| CY2015Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
1727 | |
| CY2016Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-65322 | |
| CY2015Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-1727 | |
| CY2016Q1 | us-gaap |
Repayments Of Notes Payable
RepaymentsOfNotesPayable
|
69061 | |
| CY2015Q1 | us-gaap |
Repayments Of Notes Payable
RepaymentsOfNotesPayable
|
71902 | |
| CY2015Q1 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
62600 | |
| CY2016Q1 | us-gaap |
Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
|
1119 | |
| CY2016Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
-70180 | |
| CY2015Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
-9302 | |
| CY2016Q1 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-2650470 | |
| CY2015Q1 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-1290979 | |
| CY2014Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
6262445 | |
| CY2015Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
4971466 | |
| CY2016Q1 | us-gaap |
Interest Paid
InterestPaid
|
6430 | |
| CY2015Q1 | us-gaap |
Interest Paid
InterestPaid
|
979 | |
| CY2016Q1 | us-gaap |
Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
|
11638 | |
| CY2016Q1 | us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
112720 | |
| CY2016Q1 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">NATURE OF OPERATIONS</p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Business</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corbus Pharmaceuticals Holdings, Inc. (“CPHI” or “the Company”) is a clinical stage pharmaceutical company, focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Since its inception, the Company has devoted substantially all of its efforts to business planning, research and development, recruiting management and technical staff, acquiring operating assets and raising capital. The Company’s business is subject to significant risks and uncertainties and the Company will be dependent on raising substantial additional capital before it becomes profitable and it may never achieve profitability.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the opinion of management of the Company, the accompanying unaudited condensed consolidated interim financial statements reflect all adjustments (which include only normal recurring adjustments) necessary to present fairly, in all material respects, the consolidated financial position of the Company as of March 31, 2016 and the results of its operations and cash flows for the three months ended March 31, 2016 and 2015.  The December 31, 2015 condensed consolidated balance sheet was derived from audited financial statements.  Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted.  It is suggested that these condensed consolidated financial statements be read in conjunction with the financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2015, filed on March 28, 2016.  The results of operations for such interim periods are not necessarily indicative of the operating results for the full fiscal year.</p></div> | |
| CY2016Q1 | us-gaap |
Cash
Cash
|
87461 | |
| CY2015Q4 | us-gaap |
Cash
Cash
|
255943 | |
| CY2016Q1 | us-gaap |
Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
|
9600344 | |
| CY2016Q1 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<div> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The process of preparing financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of assets and liabilities at the date of financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates and changes in estimates may occur. The most significant estimates are related to stock based compensation and the accrual of research and clinical obligations.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the registration of its common stock and the subsequent public listing of the common stock, the Company had granted stock options at exercise prices not less than the fair value of its common stock as determined by the board of directors, with input from management. The Company’s board of directors determined the estimated fair value of the common stock based on a number of objective and subjective factors, including external market conditions affecting the biotechnology industry sector and the historic prices at which the Company sold shares of preferred stock.</p></div> | |
| CY2015Q4 | us-gaap |
Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
|
12082332 | |
| CY2016Q1 | us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
1 | |
| CY2016Q1 | us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<div> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentrations of Credit Risk</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has no significant off-balance-sheet concentration of credit risk such as foreign exchange contracts, option contracts or other hedging arrangements. The Company may from time to time have cash in banks in excess of Federal Deposit Insurance Corporation insurance limits.</p></div> | |
| CY2016Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
2.55 | |
| CY2016Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
|
0.90 | |
| CY2016Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P8Y3M22D | |
| CY2016Q1 | us-gaap |
Marketable Securities
MarketableSecurities
|
0 | |
| CY2016Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
|
P7Y5M9D | |
| CY2016Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
3920264 | |
| CY2016Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
|
2130712 | |
| CY2016Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
1.40 | |
| CY2016Q1 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
|
2128624 | |
| CY2016Q1 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
|
P3Y1M2D | |
| CY2016Q1 | us-gaap |
Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
|
1967375 | |
| CY2016Q1 | crbp |
Warrants Weighted Average Exercise Price
WarrantsWeightedAverageExercisePrice
|
0.97 | |
| CY2016Q1 | crbp |
Warrants Weighted Average Remaining Contractual Term
WarrantsWeightedAverageRemainingContractualTerm
|
P3Y1M6D | |
| CY2016Q1 | crbp |
Deferred Tax Assets Valuation Allowance Percentage
DeferredTaxAssetsValuationAllowancePercentage
|
1.00 | |
| CY2016Q1 | us-gaap |
Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
|
0 | |
| CY2015Q4 | us-gaap |
Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
|
0 | |
| CY2016Q1 | us-gaap |
Asset Impairment Charges
AssetImpairmentCharges
|
0 | |
| CY2015Q1 | us-gaap |
Asset Impairment Charges
AssetImpairmentCharges
|
0 | |
| CY2016Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-2892241 | |
| CY2015Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-1535718 | |
| CY2016Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
7120060 | |
| CY2015Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
17346696 | |
| CY2016Q1 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
334391 | |
| CY2015Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
178486 | |
| CY2016Q1 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
37857 | |
| CY2015Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
54348 | |
| CY2016Q1 | crbp |
Operating Lease Terms
OperatingLeaseTerms
|
P3Y | |
| CY2016Q1 | us-gaap |
Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
|
13728 | |
| CY2016Q1 | crbp |
Area Of Land Expected To Be Occupied
AreaOfLandExpectedToBeOccupied
|
6326 | |
| CY2016Q1 | crbp |
Expected Operating Lease Terms
ExpectedOperatingLeaseTerms
|
P5Y | |
| CY2016Q1 | us-gaap |
Line Of Credit Facility Increase Decrease For Period Net
LineOfCreditFacilityIncreaseDecreaseForPeriodNet
|
36375 | |
| CY2016Q1 | us-gaap |
Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
|
109124 | |
| CY2016Q1 | us-gaap |
Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
|
148398 | |
| CY2016Q1 | us-gaap |
Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
|
151561 | |
| CY2016Q1 | us-gaap |
Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
|
154723 | |
| CY2016Q1 | us-gaap |
Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
|
157886 | |
| CY2016Q1 | us-gaap |
Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
|
13179 | |
| CY2016Q1 | us-gaap |
Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
|
734871 | |
| CY2016Q1 | us-gaap |
Lease And Rental Expense
LeaseAndRentalExpense
|
36546 | |
| CY2015Q1 | us-gaap |
Lease And Rental Expense
LeaseAndRentalExpense
|
13725 | |
| CY2016Q1 | us-gaap |
Interest Expense Debt
InterestExpenseDebt
|
1130 | |
| CY2015Q1 | us-gaap |
Interest Expense Debt
InterestExpenseDebt
|
979 | |
| CY2016Q1 | us-gaap |
Notes Payable
NotesPayable
|
92958 | |
| CY2015Q4 | us-gaap |
Notes Payable
NotesPayable
|
162019 | |
| CY2016Q1 | us-gaap |
Long Term Notes Payable
LongTermNotesPayable
|
0 | |
| CY2015Q4 | us-gaap |
Long Term Notes Payable
LongTermNotesPayable
|
0 | |
| CY2016Q1 | crbp |
Accrued Clinical Operations And Trials Costs
AccruedClinicalOperationsAndTrialsCosts
|
1028181 | |
| CY2015Q4 | crbp |
Accrued Clinical Operations And Trials Costs
AccruedClinicalOperationsAndTrialsCosts
|
365188 | |
| CY2016Q1 | crbp |
Accrued Product Development Costs
AccruedProductDevelopmentCosts
|
141756 | |
| CY2015Q4 | crbp |
Accrued Product Development Costs
AccruedProductDevelopmentCosts
|
152018 | |
| CY2016Q1 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
60000 | |
| CY2015Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
16500 | |
| CY2016Q1 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
68051 | |
| CY2015Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
28573 | |
| CY2015Q1 | us-gaap |
Revenues
Revenues
|
0 | |
| CY2015Q2 | crbp |
Deferred Revenue Gross
DeferredRevenueGross
|
1250000 | |
| CY2016Q1 | us-gaap |
Deferred Revenue
DeferredRevenue
|
1455020 | |
| CY2015Q4 | us-gaap |
Deferred Revenue
DeferredRevenue
|
1851618 | |
| CY2016Q1 | crbp |
Issuance Of Common Stock Upon Exercise Of Options And Warrants
IssuanceOfCommonStockUponExerciseOfOptionsAndWarrants
|
693 | |
| CY2015Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
3982065 | |
| CY2016Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
1195000 | |
| CY2016Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
24380 | |
| CY2016Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
5152685 | |
| CY2016Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
|
2142468 | |
| CY2015Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
1.03 | |
| CY2016Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
1.40 | |
| CY2016Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
1.11 | |
| CY2016Q1 | crbp |
Class Of Warrant Or Right Issued
ClassOfWarrantOrRightIssued
|
0 | |
| CY2016Q1 | crbp |
Class Of Warrant Or Right Cancelled
ClassOfWarrantOrRightCancelled
|
0 | |
| CY2015Q1 | crbp |
Class Of Warrant Or Right Issued
ClassOfWarrantOrRightIssued
|
0 | |
| CY2015Q1 | crbp |
Class Of Warrant Or Right Cancelled
ClassOfWarrantOrRightCancelled
|
0 |
